X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EC5026 is a small molecule drug that is a potent and highly selective inhibitor of the sEH enzyme. It is being evaluated in phase 1 clinical trials for the treatment of acute and chronic pain.
Lead Product(s): EC5026
Therapeutic Area: Neurology Product Name: EC5026
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
No drug-related adverse events or changes in vital signs or clinical labs were observed, and the final clinical study report concludes that EC5026 is safe and well tolerated when given as a single oral dose ranging from 0.5 to 24 mg.
Lead Product(s): EC5026
Therapeutic Area: Neurology Product Name: EC5026
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
EC5026 is the first soluble epoxide hydrolase inhibitor developed to treat neuropathic pain.
Lead Product(s): EC5026
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
